

Zoonotic Risk Assessment of 2.3.4.4b H5Nx Avian Influenza-A Viruses Reveals Intermediate Host Systems as Key Determinants of Productive Replication in Primary Human Lung Tissues

Monday, September 14, 2026 1:43 PM (1 minute)

Clade 2.3.4.4b H5Nx highly pathogenic avian influenza viruses (HPAIVs) have diversified extensively during global spread, yet the determinants of their zoonotic potential remain incompletely understood. We characterized eleven genetically distinct H5Nx isolates collected in Germany between 2016 and 2021 using comparative genomics and physiologically relevant human respiratory models. Despite representing multiple reassortant lineages with some substitutions linked to mammalian fitness, none encoded canonical mammalian-adaptive markers PB2-E627K, PB2-D701N, or PB2-Q591K. All isolates replicated efficiently in avian and mammalian cell lines regardless of propagation history. In contrast, primary human lung explants and differentiated nasal epithelial air-liquid interface cultures revealed a propagation-dependent phenotype: Egg-derived viruses exhibited no infectivity, while the same isolates propagated in MDCK cells established productive infection in both upper and lower respiratory tract models. Repropagation in eggs restored the restricted phenotype without adaptive mutations, implying reversible host-dependent factors, potentially including glycosylation-related changes. All viruses exhibited susceptibility to oseltamivir. These findings identify propagation host as a key determinant of 2.3.4.4b H5Nx infectivity in human respiratory tract, highlighting the value of primary human respiratory models for improving zoonotic risk assessment beyond genomic surveillance alone.

Keywords

H5Nx Viruses, Zoonotic Potential, Avian Influenza, Human Lung, ex vivo Infection

Professional status of the speaker

Postdoc

Junior scientist status

No, I am not a junior scientist.

Registration ID

Inf26-0027

Authors: Dr KUMAR, Sriram (Immunology of Respiratory Tract Infections, University Hospital Gießen and Marburg, Germany); Dr ÇALIŞKAN, Duygu Merve (Institute of Virology, University Hospital Münster, University of Münster, Germany); Dr ANHLAN, Darisuran (Institute of Virology, University Hospital Münster, University of Münster, Germany); Ms CHRISTERSSON, Anmari (Institute of Virology, University Hospital Münster, University of Münster, Germany); Dr HINSE, Saskia (Immunology of Respiratory Tract Infections, University Hospital Gießen and Marburg, Germany); Ms LEIPE, Pia Madeleine (Institute of Virology, University Hospital Münster, University of Münster, Germany); Dr KÖTHE, Susanne (Institute of Diagnostic Virology, Friedrich Loeffler Institute, Greifswald, Germany); Ms KRÜGER, Vera (Department of Thoracic Surgery and Lung Support, Ibbenbüren Hospital, Germany); Prof. FISCHER, Stefan (Department of Thoracic Surgery and Lung Support, Ibbenbüren Hospital, Germany); Prof. LUDWIG, Stephan (Institute of Virology, University Hospital Münster, University of Münster, Germany); Prof. HARDER, Timm (Institute of Diagnostic Virology, Friedrich Loeffler Institute, Greifswald, Germany); Prof. BEER, Martin (Institute of Diagnostic Virology, Friedrich Loeffler Institute, Greifswald, Germany).

many); Prof. BRUNOTTE, Linda (Immunology of Respiratory Tract Infections, University Hospital Gießen and Marburg, Germany)

Presenter: Dr KUMAR, Sriram (Immunology of Respiratory Tract Infections, University Hospital Gießen and Marburg, Germany)

Session Classification: Poster viewing

Track Classification: Epidemiology and emerging viruses